Targeted Expansion Pain and Cardiac doctors, Rehab and Senior Living facilities are the most impactful segments for HMA Genetics, presenting a clear opportunity to expand on-site testing adoption, collaboration with hospital groups, and integration into long-term care settings.

Onsite Lab Growth Develop the HOPD model to build LCMS labs within practices or hospital centers, enabling faster turnaround, closer physician integration, and higher volume of pharmacogenomics and CGx testing with reduced external lab dependency.

Personalized Medicine Value Position the company as a provider of actionable pharmacogenomics and CGx data that directly supports right drug, right dose, right time decisions, aligning with value-based care trends and payer interest in improved outcomes.

Partnership Network Leverage established relationships across multiple states and the cost of navigating provider networks by offering turnkey partnerships, white-label services, and collaborative testing programs that fit diverse health systems and PCPs.

SMB Focused Outreach With a small team footprint yet broad service scope, target mid-market hospitals, rehab clinics, and senior living operators with scalable, repeatable testing bundles and clear ROI messaging to drive rapid sales cycles.